ASCO 2024: Focus on Lung Cancer
ASCO 2024: Focus on Lung Cancer
Advertisement
Luis Paz-Ares, MD, PhDSmall Cell Lung Cancer | August 13, 2024
Dr. Paz-Ares shares his insights on recent studies and highlights practice-changing data in lung cancer.
View More
Millie Das, MDASCO 2024: Focus on Lung Cancer | August 6, 2024
A panel of experts shares their insights on key developments and advances in lung cancer treatment research.
Millie Das, MDASCO 2024: Focus on Lung Cancer | August 6, 2024
Experts discuss important management considerations and the importance of working with a multidisciplinary team.
Millie Das, MDASCO 2024: Focus on Lung Cancer | August 6, 2024
The panel discusses key questions about NSCLC treatment regimens and the research that could answer them.
Millie Das, MDASCO 2024: Focus on Lung Cancer | August 6, 2024
Experts weigh in on the long-term results presented at the 2024 American Society of Clinical Oncology Annual Meeting.
Millie Das, MDASCO 2024: Focus on Lung Cancer | August 6, 2024
The panel discusses combination therapies and treatment considerations for patients without targetable mutations.
Millie Das, MDASCO 2024: Focus on Lung Cancer | August 6, 2024
Experts weigh in on unmet needs and what clinicians should consider when treating patients who lack driver mutations.
Millie Das, MDASCO 2024: Focus on Lung Cancer | August 6, 2024
An expert panel discusses treatment and quality-of-life considerations, as well as what to do while awaiting NGS results.
Millie Das, MDASCO 2024: Focus on Lung Cancer | August 6, 2024
Experts weigh in on NSCLC screening and diagnostic challenges and the prevalence of metastatic disease at diagnosis.
Katie KoskoNon-Small Cell Lung Cancer | July 30, 2024
Researchers say the results support the evaluation of the treatment in the phase 3 CodeBreaK 202 trial.
Katie KoskoNon-Small Cell Lung Cancer | July 25, 2024
Study investigators say that extended follow-up research on nivolumab consolidation is essential.
Luis Paz-Ares, MD, PhDNon-Small Cell Lung Cancer | July 23, 2024
Dr. Paz-Ares shares his insights on the study's results and the remaining questions about ADCs in lung cancer treatment.
Yuanbin Chen, MD, PhDASCO 2024: Focus on Lung Cancer | July 18, 2024
The CheckMate 9LA study evaluated first-line nivolumab plus ipilimumab with 2 cycles of platinum-doublet chemotherapy.
Leah LawrenceNon-Small Cell Lung Cancer | July 12, 2024
Researchers compared outcomes between patients with baseline stage III N2 and non-N2 NSCLC.
Katie KoskoASCO 2024: Focus on Lung Cancer | July 8, 2024
Most patients who received adjuvant osimertinib achieved MRD negativity.
Katie KoskoASCO 2024: Focus on Lung Cancer | July 5, 2024
More than half of patients in the study had psychological distress as well as elevated serum cortisol levels.
Katie KoskoASCO 2024: Focus on Lung Cancer | July 4, 2024
Researchers assessed patients' functional health and well-being across multiple physical and mental domains.
Leah LawrenceASCO 2024: Focus on Lung Cancer | July 3, 2024
A pilot study evaluated neoadjuvant platinum, pemetrexed, and nivolumab followed by pleurectomy/decortication.
Leah LawrenceASCO 2024: Focus on Lung Cancer | July 2, 2024
Study investigators say the results support further study of the bispecific T-cell engager in previously treated SCLC.
David R. Spigel, MDASCO 2024: Focus on Lung Cancer | July 1, 2024
Dr. Spigel speaks about how the American Society of Clinical Oncology Annual Meeting inspires collaboration and discovery.
Advertisement
Advertisement
Advertisement
Latest News

October 4, 2024